Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Resveratrol Plus Carboxymethyl-beta-Glucan in Children With Allergic Rhinitis
NCT03349619Phase 4Completed
- Sponsor
- CNR-Institute for Biomedical Research and Innovation
- Start
- Mar 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of resveratrol 1% gel, carboxymethylated β-glucan in allergic rhinitis (AR), sponsored by CNR-Institute for Biomedical Research and Innovation. Started Mar 2018; status: completed.
02
Drugs
resveratrol 1% gelcarboxymethylated β-glucan
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT03349619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03349619.